p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression
- PMID:9036865
- DOI: 10.1002/(sici)1097-0215(19970220)74:1<26::aid-ijc5>3.0.co;2-2
p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression
Abstract
The p16/CDKN2(MTS1) gene encoding for the p16 inhibitor of cyclin D/CDK4 complexes is frequently mutated and deleted in a large fraction of melanoma cell lines, and p16 germline mutations have also been observed in familial melanomas. Moreover, a CDK4 gene mutation, responsible for a functional resistance of CDK4 kinase to p16 inhibitory activity, has been described to occur in some cases of familial melanoma. These data strongly support the idea that deregulation of the CDK4/cyclin D pathway, via CDKN2 or CDK4 mutations, is of biological significance in the development of melanoma. To shed light on the role of these alterations in the development and progression of sporadic melanoma, 12 primary melanomas and 9 corresponding metastases were analyzed for CDKN2 and CDK4 gene mutations. Of the 12 primary melanomas analyzed, 4 showed the presence of mutational inactivation of the p 16 protein and 2 carried silent mutations. No metastases showed the presence of CDKN2 mutations, indicating that mutations of this cyclin-dependent kinase inhibitor is not common in the progression of sporadic melanoma. On the other hand, the absence, in the metastases, of the CDKN2 mutation detected in the corresponding primary tumors suggests that 9p21 homozygous deletion may play a major role in the metastatic spreading of this type of tumor. None of the cases analyzed showed the presence of an Arg24Cys mutation, which functionally protects CDK4 from p16 inhibition. This indicates that CDK4 mutation plays a minor role in the development and progression of sporadic melanoma.
Similar articles
- Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O.Maelandsmo GM, et al.Br J Cancer. 1996 Apr;73(8):909-16. doi: 10.1038/bjc.1996.181.Br J Cancer. 1996.PMID:8611425Free PMC article.
- The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J.Bartkova J, et al.Cancer Res. 1996 Dec 1;56(23):5475-83.Cancer Res. 1996.PMID:8968104
- MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, Bruce J, Tycko B.Moulton T, et al.Am J Pathol. 1995 Mar;146(3):613-9.Am J Pathol. 1995.PMID:7887443Free PMC article.
- [p16(INK4A)/CDKN2--the "melanoma gene"? Status of research and outlook].Bogenrieder T, Landthaler M, Stolz W.Bogenrieder T, et al.Hautarzt. 1998 Feb;49(2):91-100. doi: 10.1007/s001050050706.Hautarzt. 1998.PMID:9551329Review.German.
- Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.Pollock PM, Pearson JV, Hayward NK.Pollock PM, et al.Genes Chromosomes Cancer. 1996 Feb;15(2):77-88. doi: 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0.Genes Chromosomes Cancer. 1996.PMID:8834170Review.
Cited by
- Towards a Better Understanding of the Molecular Mechanisms Involved in Sunlight-Induced Melanoma.Williams M, Ouhtit A.Williams M, et al.J Biomed Biotechnol. 2005;2005(1):57-61. doi: 10.1155/JBB.2005.57.J Biomed Biotechnol. 2005.PMID:15689639Free PMC article.
- Expression of p16 in sinonasal malignant melanoma.Franchi A, Alos L, Gale N, Massi D, Paglierani M, Santucci M, Zidar N, Cardesa A.Franchi A, et al.Virchows Arch. 2006 Dec;449(6):667-72. doi: 10.1007/s00428-006-0288-0. Epub 2006 Nov 8.Virchows Arch. 2006.PMID:17091256
- Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions.Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T.Sano T, et al.Am J Pathol. 1998 Dec;153(6):1741-8. doi: 10.1016/S0002-9440(10)65689-1.Am J Pathol. 1998.PMID:9846965Free PMC article.
- The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression?Choi KH, Kim GM, Kim SY.Choi KH, et al.Cancer Res Treat. 2010 Jun;42(2):107-14. doi: 10.4143/crt.2010.42.2.107. Epub 2010 Jun 30.Cancer Res Treat. 2010.PMID:20622965Free PMC article.
- Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?van Engen-van Grunsven AC, Kusters-Vandevelde H, Groenen PJ, Blokx WA.van Engen-van Grunsven AC, et al.Front Med (Lausanne). 2014 Oct 31;1:39. doi: 10.3389/fmed.2014.00039. eCollection 2014.Front Med (Lausanne). 2014.PMID:25593912Free PMC article.Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous